Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 18, 2003HeartOpen Access

Treatment of chronic heart failure with β adrenergic blockade beyond controlled clinical trials: the BRING-UP experience

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does beta-blocker therapy improve mortality and hospital admissions in patients with heart failure in real-world general cardiology care?

Population

n=3,091 consecutive heart failure patients seen in general cardiology care over a one-month period

Comparison

Beta-blocker therapy prescribed at physician… vs Heart failure patients not receiving…

Design

Cohort

Follow-up

1 year

Authors

AMAldo P. MaggioniUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Overview

Supports beta-blocker use in real-world HF; extends trial data but leaves open causality without randomized confirmation.

Structured PICO

Does beta-blocker therapy improve mortality and hospital admissions in patients with heart failure in real-world general cardiology care?

P
Population
n=3,091 consecutive heart failure patients seen in general cardiology care over a one-month period
I
Intervention
Beta-blocker therapy (carvedilol, metoprolol, or bisoprolol) prescribed at physician discretion
C
Comparator
Heart failure patients not receiving beta-blocker therapy
O
Outcome
Mortality and hospital admissions for worsening heart failure at 1 yearhard clinical

The implementation of beta-blockers in real-world clinical practice is feasible and associated with reduced mortality and hospital admissions for heart failure, mirroring clinical trial results.

Cite This Study

Aldo P. Maggioni (2003) studied this question.

synapsesocial.com/papers/6a817801762dba2aae6493eahttps://doi.org/10.1136/heart.89.3.299
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?2016 · 871 citations
  2. 2Major β blocker mortality trials in chronic heart failure: a critical review1999 · 46 citations
  3. 3Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade1995 · 536 citations
  4. 4Effect of Carvedilol on Survival in Severe Chronic Heart Failure2001 · 3,108 citations
  5. 5A Comparison of Observational Studies and Randomized, Controlled Trials2000 · 2,357 citations